Medical University of Lublin   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Lublin Poland (1944)

Organization Overview

First Clinical Trial
2001
NCT00559351
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

2nd Department of General, Gastrointestinal Surgery & Surgical Oncology of the Digestive Tract, Medical University of Lublin, Poland | Department of Neonate and Infant Pathology, Medical University of Lublin, Poland | IInd Department of Gynecology, Medical University of Lublin, Poland | Medical University of Lublin | Medical University of Lublin, Poland | Michał Borys | Second Department of General & Gastrointestinal Surgery & Surgical Oncology of the Alimentary Tract, Medical University of Lublin

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Atrial Fibrillation (Phase 4)

Carcinoma, Squamous Cell (Phase 3)

Cataract (Phase 2)

Esophageal Neoplasms (Phase 3)

Eye Diseases (Phase 1)

Glaucoma (Phase 1)

Infertility (Phase 2)

Neoplasms, Squamous Cell (Phase 3)

Neuralgia (Phase 4)

Pain, Postoperative (Phase 4)

Polycystic Ovary Syndrome (Phase 2)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Stomach Neoplasms (Phase 3)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 35